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Abstract:
Objective: To study the effect of ketamine in
patients of severe wheezing due to bronchioli-
tis who are refractory to the standard treatment.
Methods: Prospective study including 104 chil-
dren between 2 months to 2 years who pre-
sented to us with severe wheezing due to bron-
chiolitis. Initially they were treated with humidi-
fied oxygen and adrenaline nebulisation. Chil-
dren with no response after 48 hours were given
intravenous ketamine as a bolus in dose of 1
mg/kg. Patients were monitored with Uyan
score and oxygen saturation for 1 hour and those
without considerable improvement were given
continuous infusion at 10 ìgm/kg/min. Results:
104 patients were identified with severe wheez-
ing due to bronchiolitis during study period. 84
(81%) patients responded well to standard
treatment. 20 (19%) patients who did not im-
prove were treated with ketamine. All patients
responded to intravenous ketamine as bolus and
showed noticeable improvement in 1 hour with
improvement in scoring parameters. 14 (70%)
patients had to be given infusion of ketamine
and they were gradually weaned off the drip in
an average of 15 hours. Conclusion: Use of
ketamine in patients with severe wheezing due
to bronchiolitis who failed to respond to stan-
dard treatment showed improvement which ob-
viated the need for intubation and mechanical
ventilation.
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Introduction:
Infants are more prone to wheeze, owing to dif-
ferent set of lung mechanism as compared to
older children and adults. The obstruction to
flow is affected by airway caliber and compli-
ance of the infant lung. Wheezing is common
in infants and there are no specific guidelines
for treatment of such patients [1].  Response to
bronchodilators is unpredictable, regardless of
cause, but suggests a component of bronchial
hyper reactivity. Ketamine, is a Phenacyclidine
derivative and an intravenous anesthetic [2].
Ketamine was synthesized in 1962, by Stevens
and was first used in humans by Crossen and
Dommino, in 1965 [3].  It was released for clini-
cal used in 1970 and is still used in variety of
clinical setting [2].  It has also been demon-
strated to cause bronchodilation thereby reduc-
ing airway resistance and increases lung com-
pliance [4, 5]. Ketamine has been successfully
used in management of acute severe asthma in
adults and children but rarely used in infants with
refractory wheezing due to bronchiolitis [1]. For
this reason we designed a prospective observa-
tional study in patients presenting to us with
refractory wheezing due to bronchiolitis unre-
sponsive to standard treatment.
Material and Methods:
The study was conducted in the pediatric inten-
sive care unit of Krishna Hospital, Karad
Maharashtra. The study was conducted between
November 2011 and September 2012. Children
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aged 2 months to 2 years, presenting with first
episode of wheezing with respiratory distress
were considered for the study. Chest radiograph
was done for all patients which showed bilat-
eral hyperinflation suggestive of bronchiolitis.
The children were initially treated with humidi-
fied oxygen and nebulisation with adrenaline.
This treatment was continued for 48 hours. Our
patients were monitored by Uyan score [6] and
oxygen saturation (SpO2) with FiO2 of 0.6. As
the patient profile in our hospital comes from
low socioeconomic strata we could not use in-
vasive parameters like arterial blood gases for
monitoring the patients due to financial con-
strains.
The patients who did not respond to conven-
tional method of treatment as mentioned above
were considered for Ketamine use. A Uyan score
of 9 was taken as a cut off for use of Ketamine.
A total of 20 patients were considered for
Ketamine use. An informed parental consent
was obtained for the same. Patients with con-
genital heart disease, central nervous system
problems (increased intracranial pressure, in-
tracranial mass lesions), and patients with other
contraindications to Ketamine like vascular an-
eurysms, open eye injury or other ophthalmic
disorders, in which a Ketamine induced increase
in intraocular pressure would be detrimental
hence were excluded. Patients with family or
personal history of asthma or atopy were also
excluded.
Patients were given intravenous ketamine as 1
mg/kg bolus and improvement in Uyan score
and SpO2 were monitored after 1 hour. Those
patients who did not have improvement in Uyan
score > 9 were considered for infusion.
Ketamine was infused at a rate of 10ì/kg/min.
Although in this study we did not use control
group, the patients respiratory variables were
measured with parameters like Uyan score and
SpO2 prior to and one hour after Ketamine in-
fusion and after weaning off the Ketamine. Data
were analyzed using SPSS software and were
expressed as mean ± standard deviation (SD)
and compared using, unpairedt test and re-
peated measure ANOVA test. Comparison was
done on the basis of Bonferroni correction and
statistical significance was considered at p <
0.05.
Results:
One hundred four patients presented with se-
vere wheezing with respiratory distress during
the study period. Eighty four (81%) patients
responded to standard treatment. Twenty (19%)
patients were enrolled for Ketamine use who
failed to respond with the standard therapy. Six
(30%) patients responded to IV Ketamine bo-
lus leaving fourteen (70%) patients for
Ketamine infusion. The details of these patients,
Uyan score and SpO2 at three intervals namely
prior to Ketamine use (T0), one hour after
Ketamine infusion (T1) and at the time when
Ketamine was weaned off (TW) are given in Table 1.
The mean valves obtained for Uyan score at T0,
T1 and TW were 13.14 ± 1.17, 9.82 ± 1.21 and
0.5 ± 0.65 respectively. The mean valves ob-
tained for SpO2 at T0, T1 and TW were 87.71%
± 2.05%, 92.64% ± 2.46% and 99.5% ± 0.51%
respectively. This showed that there were
gradual improvements in the Uyan score and
progressive rise in the oxygen saturation after
Ketamine use (Figures 1A and 1B).
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Average
F
p-value
Uyan Score Oxygen Saturation
Wean hrs Sex
T0
Males
Females
Unpaired t value
p - value
SD
T1
Mean SD
TW
Mean SD
T0
Mean SD
T1
Mean SD
TW
Mean SD Mean
1.27
1.10
1.34
0.82
10.00
13.20
0.29
0.78
1.22
1.10
1.13
0.81
0.33
0.80
1.32
0.21
0.50
0.84
2.80
0.20
88.44
86.40
1.97
0.07
1.88
1.82
1.07
>0.99
2.89
1.64
3.10
0.29
49.56
63.40
0.52
0.61
46.91
48.75
1.08
0.85
13.11
13.20
0.13
0.90
Mean SD
15.78
14.80
0.16
0.88
12.82
6.87
3.48
0.24
92.89
92.20
0.05
0.64
Table 1: Sexwise Distribution of Mean Uyan Score, Mean % Oxygen Saturation & Mean Wean Hrs
Uyan Score Oxygen Saturation
Wean hrs Age in
months T0
SD
T1
Mean SD
TW
Mean SD
T0
Mean SD
T1
Mean SD
TW
Mean SD Mean
1.16
0.98
1.52
1.17
10.33
9.17
10.60
9.93
1.53
0.41
1.34
1.21
0.67
0.17
0.80
0.5
1.16
0.41
0.45
0.65
88.67
87.00
88.00
87.71
1.53
2.45
1.87
2.05
1.16
2.93
1.92
2.47
99.33
99.67
99.40
99.5
0.58
0.52
0.55
0.52
12.67
13.17
13.40
13.14
Mean SD
8.67
10.67
25.20
15.43
3.06
7.00
11.10
10.77
92.67
93.83
91.20
92.64
Table 2: Agewise Distribution of Mean Uyan Score, Mean % Oxygen Saturation & Mean Wean Hrs
Sr.
No. No.
3
6
5
<6
>6to12
>12to24
1
2
3
Uyan Score SpO2
0.33
0.72
2.70
0.11
1.54
0.26
0.70
0.52
1.73
0.22
0.52
0.61
5.46
0.023*
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Figure 1A & 1B Mean and 95% CI of Uyan Score and SpO2 at A- prior to Ketamine Use B-
One Hour after Ketamine Use and C-Weaned off from Ketamine.
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There was no significant difference in two
sexes as judged by unpaired t test for the mean
and SDs of Uyan score , Oxygen Saturation and
Weaning time.
When consideration was given to age groups
between 2 months to < 6 months, > 6 months
to < 12 months & > 12 months, it was observed
that there was a significantly lesser weaning
time at the earlier ages. With increasing age the
weaning time of Ketamine drip also increased.
There was no significant difference in the mean
Uyan scores and mean oxygen saturation val-
ues in different age groups. (Table 2)
Repeated ANOVA test was applied to the data
of patients of the two parameters studied
namely Uyan score and oxygen saturation which
showed an F value of 1096.5 for Uyan score
and 167.07 for oxygen saturation. Further, this
was supported by Bonferroni correction which
was applied to the Uyan score and oxygen satu-
ration readings at three intervals and the statis-
tical differences between the intervals were
compared and it was found that both the param-
eters were statistically significant. (Table 3 and
4) Bonferroni correction was found statistically
significant signifying that given result is un-
likely to have occurred by chance.
Mean
difference
Groups F Bonferroni p
Table 3: ANOVA Test Application on Uyan Score
3.214
12.643
9.429
T0 vs T1
T0 vs TW
T1vsTW
11.454
45.051
33.598
<0.001
<0.001
<0.001
1096.5
Mean
difference
Groups F Bonferroni p
Table 4: ANOVA Test Application on Oxygen
Saturation
-4.929
-11.786
-6.857
T0 vs T1
T0 vs TW
T1vsTW
7.610
18.198
10.588
<0.001
<0.001
<0.001
167.07
Discussion:
Wheezing in infants and children is common
and can be due to bronchiolitis (viral infection),
chlamydial infection, congenital airway and
heart anomalies, mediastinal masses and for-
eign body aspiration. There are no specific
guidelines for treatment of acutely wheezing
infants [1]. Chest radiogram of all our patients
revealed bilateral hyperinflation suggestive of
bronchiolitis. Thus all patients were treated with
standard treatment of humidified oxygen and
adrenaline nebulisation. Eighty four (81%) of
the 104 patients showed improvement by the
standard treatment while 20 patients did not
show signs of improvement or detoriated to-
wards respiratory failure. Betts and Parkin in
1971 has first used Ketamine as an anesthetic
agent in a 5 years old asthmatic patient which
relieved the bronchospasm [7]. In a years pe-
riod Corssen (1972) has made a similar obser-
vation [4]. With the knowledge of various case
reports and randomised control trials related
to Ketamine use for acute exacerbation of
asthma in pediatric patients as well as adults the
decision of using ketamine has been
taken.[1,4,7,8,10-12,19-24]
Ketamine has many pharmacological proper-
ties, including analgesia, anesthesia and sym-
pathomimetic effect [8]. It produces functional
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and electrophysiological dissociation between
the cortical and limbic systems of the brain,
resulting in a cataleptic state [9]. Owing to its
ability to relax bronchial smooth muscle,
Ketamine is recommended as an optimizing an-
esthetic for asthmatic patients and has been
clinically used to treat bronchospasm, asthma
exacerbation and status asthmaticus [10-12]. In
recent years due to its anti-inflammatory prop-
erties studies have shown Ketamine plays an
important role against lung injury [13].
Various studies in animal tissues have been car-
ried out to determine the mechanism by which
Ketamine produces bronchodilation. In a study
on canine trachea, significant relaxation of
smooth muscle has been seen with an associ-
ated decrease intracellular calcium concentra-
tion after Ketamine administration [14]. An-
other study has been performed on tracheal
smooth muscle of female guinea pigs which has
demonstrated that Ketamine helps in relaxation
of smooth muscle fiber inspite of blockade of
Table 5: Various Studies Conducted C Ketamine in Patients of Bronchospasm
Measures of
Improvement Author/Yr Pt Age Study Design Dose Duration Intubation
Fisher
1977 19
Rock et al
1986 20
Nehama et
al 1996 21
Youssef et
al 1996 10
Petrillo et al
2001 22
Jat KR et
al 1
Present
study
1
2
1
17
10
1
20
5 yr
4 &10 yr
8 months
5 mth-
17 yr
-
2 months
2m-24 m
Case Report
Case Report
Case Report
RCT
POS
Case report
POS
200 mg iv
bolus
0.5-1 mg/kg
(B)
1mg/kg/hr(I)
1.4mg/kg(B)
0.2 mg/kg/hr
 0.15
mg/kg/hr
2mg/kg (B)
20-60
ì g/kg/m (I)
1mg/kg (B)
0.75mg/kg(I)
1 mg/kg (B)
10-15
ì g/kg/m
 (I)
1mg/kg (B)
10 ì g/kg/m
(I)
bolus
24 hr
40 hr
variable
1 hr
48 hrs
15 hr
Yes
Yes
Yes
Yes
No
No
NO
ABG
RR, TV, ABG
 PIP, Pco2, 
expansion,
 wheeze
Gas xnge
Compl.
RR , PEF
RR,  SPO2,
wheezing
UYAN SCORE,
SPO2
RCT-Randomised Control Study, POS- Prospective Observational Study, ABG-Arterial Blood Gases, RR-Respiratory Rate,
TV-Tidal Volume, PIP- Peak Inspiratory Pressure, PEF- Peak Expiratory Flow, SPO2- Oxygen Saturation
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nitric oxide synthase by N-omega-nirto-L-argi-
nine methyl ester (L-NAME), a potent NO syn-
thase inhibitor, thus relaxes airway smooth
muscle via an epithelial independent mechanism
[15]. Other studies on dogs and female guinea
pigs showed inhibitory effect of Ketamine on
mediator release from mast cells [16] but not
to the stimulation of N-Methyl-D-Aspartic acid
(NMDA) on tracheal muscles [17]. Thus in
spite of all these studies the mechanism by
which Ketamine produces airway relaxation is
still unclear although it is best attributed to in-
creased catecholamine concentrations, inhibi-
tion of catecholamine uptake, voltage-sensitive
Ca2+ channel block and inhibition of postsyn-
aptic nicotinic or muscarinic receptors [18].
Several case reports and studies have been con-
ducted on both ventilated and non-ventilated
patients who failed to respond to standard
therapy.  Studies conducted on patients of pe-
diatric age have been shown in Table 5.
Most of these patients have been established
cases of bronchial asthma.  Expect for a study
conducted by Youssef- Ahmed et al (1996)
where Ketamine has been used in 17 mechani-
cally ventilated patients with refractory bron-
chospasm where 4 patients have had respira-
tory syncytial virus bronchiolitis and 2 patients
have had bronchial pneumonia. Improvements
in gas exchange, paO2/FiO2 ratio and improve-
ments in dynamic compliance have been ob-
served in all the patients [10].
In 2001 Petrillo et al have conducted a pro-
spective observational study in 10 pediatric pa-
tients refractory to standard therapy for status
asthmaticus and have shown that after Ketamine
infusion there has been a significant decrease
in clinical asthma score, respiratory rate, oxy-
gen requirement and peak expiratory flow [22].
Howten et al have conducted a double blind  pla-
cebo controled trial in 53 adult patients and have
concluded that intravenous ketamine at low
doses demonstrates no increase in bronchodi-
lator effect over standard therapy. This study
states that Ketamine is not an adjuvant therapy
for patients with acute asthma exacerbation and
it does not address the potential efficacy of
Ketamine as a medication of last resort [23].
In the present study we have found an improve-
ment in the Uyan score which takes into ac-
count five important parameters like respira-
tory rate, wheezing, retractions, nasal flaring
and general status. Thus it implies that the res-
piratory distress of the patient has relieved and
ventilation has improved which is reflected in
the improvement of SpO2.
But some studies have suggested no role of
Ketamine in their studies such as; Allen et al
(2005) who have conducted a double-blind,
randomized, placebo-controlled trial in 68 pa-
tients aged 2 to 18 years, with 33 randomized
to the Ketamine infusion and 35 randomized
to placebo. All patients have received a bolus
of 0.2 mg/kg of Ketamine, followed by a 2-
hour Ketamine infusion at 0.5 mg/kg per hour
or an equal-volume regimen with normal-saline
placebo. Authors have concluded that on these
doses no incremental benefit has been seen
over the standard therapy in this cohort of chil-
dren with a moderately severe asthma exacer-
bation [24].
Jat et al (2012) in an intervention review for
Ketamine for management of acute exacerba-
tions of asthma in children have found that there
is no significant benefit and does not support
the case studies and observational reports show-
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ing benefits of ketamine in both non-ventilated
and ventilated children, and has concluded that
to prove that Ketamine is an effective treat-
ment for acute asthma in children, there is need
for sufficiently powered randomised trials of
high methodological quality with objective out-
come measures of clinical importance [25].
Ketamine is relatively safe in children and the
side effects are generally mild like laryn-
gospasm, emergency reactions, agitation which
are self-limiting [26, 27]. The emergence of
reactions like confusion, delirium, excitement,
hallucinations, irrational behaviour, agitation or
pleasant dream-like state may be observed of-
ten in older children over 10 years of age and
adults, but are very uncommon in younger chil-
dren [28]. Due to the NMDA receptors antago-
nistic activity of Ketamine, it may cause
apoptosis of newborn brain hence it has been
not used in any patient below 2 months of age [29].
The side-effects we have experienced have been
increased secretions, tachycardia in all the pa-
tients and aspiration in two patients. With the
aim of decreasing airway secretions atropine
and for prevention of psychologic emergence
midazolam can be used, but none of these medi-
cations have been used in our study. Limitation
of this study has been the inability to test for
nasopharyngeal secretions mainly for respira-
tory syncytial virus due to unavailability of the
required test.
Conclusion:
 All the studies conducted previously have been
mostly in patients of established bronchial
asthma with exception of a few. We have con-
ducted the study on patients who presented with
wheezing mainly due to bronchiolitis and have
been refractory to standard treatment. The use
of Ketamine in all patients has been successful
and has obviated the need for intubation and
mechanical ventilation. The drug has been only
used when the other drugs have failed to show
a response and the patients have been continu-
ously monitored. Adverse effects of Ketamine
may cause harmful effects, hence it is better to
use it in a set-up with easy availability of artifi-
cial ventilation. And before recommending use
of Ketamine routinely a well designed random-
ized control study needs to be conducted in pe-
diatric age group to ascertain the efficacy and
determine the dose in pediatric age group.
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